Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00183820
Other study ID # 4T-03-1
Secondary ID
Status Completed
Phase Phase 2
First received September 9, 2005
Last updated July 5, 2017
Start date November 2004
Est. completion date August 2016

Study information

Verified date July 2017
Source University of Southern California
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a study for patients with advanced testicular cancer. This research study involves treatment with oxaliplatin, paclitaxel, and gemcitabine, which is an investigational chemotherapy combination. This study is for patients who have not responded to standard cisplatin-containing chemotherapy or the cancer has returned after such treatment.

This research is being done to assess the effectiveness of the proposed combination of medications for this type of cancer.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date August 2016
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender Male
Age group 16 Years and older
Eligibility Inclusion Criteria:

1. Prior histologic or serologic confirmation of testicular or extragonadal germ cell neoplasm not amenable to surgical cure

2. Must have refractory germ cell neoplasm defined as one or more of the following:

- patients who progress during or within 4 weeks of cisplatin-containing tx, OR - patients who have failed initial salvage chemotx regimens, including high-dose tx (chemotx with stem cell support), POMB-ACE tx, VeIP, or VIP

3. Must have one or more of the following (check all that apply):

- unidimensionally measurable doze assessed within 14 days prior to registration,

- elevated ß-HCG > 20 mIU assessed within 24-48 hours prior to registration, OR

- AFP > 2 x uln assessed within 5-7 days prior to registration

Note: Soft tissue dz, which has been radiated in the 2 months prior to registration, is not assessable as measurable dz.

4. X-rays, scans, or PE for non-measurable dz must have been completed within 14 days of registration

5. May have received prior surgery or RT. At least 3 weeks must have elapsed since completion of previous tx and must have recovered from any adverse effects

6. Zubrod PS less than or equal to 2

7. Greater than or equal to 16 years of age

8. AGC greater than or equal to 1.5; platelets greater than or equal to 100,000

9. Total bilirubin < 2.5 x uln; SGOT and alk phos < 5 x uln (obtained within 14 days prior to registration)

10. LDH (obtained within 7 days prior to registration)

11. Creatinine < 2.5 x uln or calc or meas CrCl greater than or equal to 40 ml/min (obtained within 14 days prior to registration; patient must not be on renal dialysis)

12. Serum K+ and Mg++ within inst range of normal (obtained within 14 days prior to registration)

13. Men of reproductive potential must agree to use effective contraceptive method

14. Signed informed consent (including HIPAA authorization)

Exclusion Criteria:

1. Prior tx with cytotoxic or experimental agents within 14 days prior to registration

2. Evidence of concurrent infection (T > 96.8F but < 101.5F; WBC < 11.0 unless these values can be ascribed to another tumor-related phenomena)

3. Other prior malignancy, except adequately treated basal cell or squamous cell skin cancer, adequately treated stage I or II cancer from which patient is currently in chemoradiation (CR), or any other cancer from which patient has been disease-free for 5 years

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
paclitaxel, gemcitabine, and oxaliplatin
Paclitaxel 170 mg/m2 IV d 1 14 days Gemcitabine 800 mg/m2 IV d 1 14 days Oxaliplatin 100 mg/m2 IV d 1 14 days

Locations

Country Name City State
United States Norris Comprehensive Cancer Center Los Angeles California

Sponsors (2)

Lead Sponsor Collaborator
University of Southern California Sanofi

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tumor Response Every 6 weeks
Secondary Progression Every 9 wks
See also
  Status Clinical Trial Phase
Recruiting NCT00772694 - Sorafenib Monotherapy in Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy Phase 2
Completed NCT00705094 - Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients N/A
Terminated NCT00531687 - Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer Phase 2
Terminated NCT00820287 - Identification of Predictive Markers for Testis Cancer in a Population of Men With High Risk N/A
Completed NCT00216801 - Relationship of Ochratoxin A to Upper Urologic Cancers N/A
Active, not recruiting NCT03142802 - Low-Dose CT - Stage I Testicular Cancer N/A
Recruiting NCT03232541 - The Effects of Acupuncture and the Therapist´s Communication on Chemotherapy Induced Nausea and Vomiting N/A
Completed NCT03557177 - Clinical Characterisation of the Vascular Effects of Cis-platinum Based Chemotherapy in Patients With Testicular Cancer
Active, not recruiting NCT01783145 - Shared Care Follow-up After Chemotherapy for Testicular Cancer
Recruiting NCT05611307 - Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors
Completed NCT02573584 - Vascular Fingerprint Validation Study
Recruiting NCT05670938 - Follow-up After Surgery for Testicular Cancer
Recruiting NCT02994758 - Development of Diagnostics and Treatment of Urological Cancers N/A
Completed NCT02991209 - Study of Testosterone vs Placebo in Testicular Cancer Survivors Phase 2/Phase 3
Completed NCT02602041 - Knowledge and Attitudes Regarding Healthy Lifestyle and Health Behavior Change in Cancer Patients and Their Partners; A Pilot Study
Completed NCT02092740 - REtrospective Study of TESTIcular CAncer Patients at the University Magdeburg N/A
Completed NCT01482741 - Understanding Patient Perspectives on the Risks of Ionizing Radiation Used for Medical Imaging N/A
Active, not recruiting NCT01242072 - Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies Phase 1
Completed NCT01242631 - Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer Phase 2
Completed NCT01135849 - B-Receptor Signaling in Cardiomyopathy N/A